Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Completed 80Terminated 15Recruiting 14Active not recruiting 13Unknown 11Withdrawn 5

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 5

Conditions

Breast Neoplasms 6Prostatic Neoplasms 5Breast Neoplasms, Male 1

Interventions

Docetaxel 11Prednisone 10Leuprolide 10Magnetic Resonance Spectroscopy 9bicalutamide 8Radiotherapy 7Abiraterone Acetate 7Biopsy 6gallium 68 PSMA-11 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Metformin 5Goserelin 5radium Ra 223 dichloride 4enzalutamide 4apalutamide 4Specimen Handling 4Injections 4Androgen Antagonists 4pembrolizumab 3orteronel 3cabazitaxel 3abiraterone 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Pioglitazone 3Paclitaxel 3Exercise 3Brachytherapy 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Prostatic Neoplasms × Goserelin × Clear all
NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

OHSU Knight Cancer Institute

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT02588404 2024-12-10

The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

Sir Mortimer B. Davis - Jewish General Hospital

Withdrawn
Genitourinary

Prostatic Neoplasms

NCT00771017 2023-05-25

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT02678520 2016-07-22

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

University of Kansas Medical Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT00255268 2007-08-28

CMAB vs IMAB in Metastatic Prostate Cancer

AstraZeneca

Phase 4 Withdrawn
15 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡